What is the difference between Tebio and Eltrombopa?

TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world. It has similar pharmacological effects as endogenous thrombopoietin and can promote platelet production.

Eltrombopag is a nonpeptide, oral thrombopoietin receptor agonist (TPO-RA).

Mechanism of action: By binding to the transmembrane domain of the thrombopoietin receptor in the human body, it activates the thrombopoietin receptor and produces physiological activities similar to thrombopoietin, thus promoting the production of platelets.

Tepio is mainly used to treat thrombocytopenia (CIT) and immune thrombocytopenia (ITP) caused by chemotherapy for solid tumors. It is usually administered via subcutaneous injection. The specific dosage and course of treatment vary depending on the disease and must be used under the guidance of a doctor.

Eltrombopag is mainly used to treat ITP patients who have low benefit from first-line treatment or who have undergone splenectomy, thrombocytopenia in patients with chronic hepatitis C (can be combined with interferon), and patients with severe aplastic anemia. For oral administration, the initial dose and maintenance dose need to be adjusted according to the patient's weight, condition, platelet count and other factors.

As a recombinant human thrombopoietin, TPIAO has a structure similar to endogenous thrombopoietin, so it has high biological activity. It requires injection, which may cause some inconvenience to the patient's life.

Eltrombopag As an orally administered form, Eltrombopag has higher patient compliance and facilitates long-term use. It may interact with other drugs, so you need to pay attention to the interaction between drugs during use.

Both TPIAO and Eltrombopag may cause adverse reactions during use, such as headache, nausea, vomiting, etc. But overall, their safety is widely recognized.

When using these two drugs, patients need to monitor their condition closely and report any symptoms to their doctor promptly.